Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review

Hematology/Oncology Clinics of North America

Volumn 30, Issue 5, 2016, Pages 1073-1084

  Bell, Benjamin R ^a   Spyropoulos, Alex C ^b   Douketis, James D ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b LENOX HILL HOSPITAL   (United States)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Algorithm; Direct oral anticoagulants; Perioperative management; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN; DALTEPARIN; DIRECT ORAL ANTICOAGULANT AGENT; EDOXABAN; ENOXAPARIN; IDARUCIZUMAB; LOW MOLECULAR WEIGHT HEPARIN; PERINDOPRIL; PLACEBO; RIVAROXABAN; TRANEXAMIC ACID; UNCLASSIFIED DRUG; WARFARIN;

ABDOMINAL PAIN; ADULT; AGED; ANTICOAGULATION; ATRIAL FIBRILLATION; BLEEDING; CASE REPORT; CATARACT EXTRACTION; CEREBROVASCULAR ACCIDENT; CHOLECYSTECTOMY; CONTROLLED STUDY; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DENTAL PROCEDURE; ELECTIVE SURGERY; FEMALE; GINGIVA BLEEDING; HEART LEFT VENTRICLE FAILURE; HEMOSTASIS; HUMAN; HYPERTENSION; ILEUS; INCIDENCE; KIDNEY FUNCTION; LAPAROSCOPIC SURGERY; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; OBESITY; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; TOOTH EXTRACTION; TRANSIENT ISCHEMIC ATTACK; VERY ELDERLY; ALGORITHM; HEMORRHAGE; ORAL DRUG ADMINISTRATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS;

ADMINISTRATION, ORAL; ALGORITHMS; ANTICOAGULANTS; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS;

EID: 84991293650     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2016.05.005     Document Type: Review

References (33)

1. 1 Chugh, S.S., Havmoeller, R., Narayanan, K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129 (2014), 837–847.
2. 2 Go, A.S., Hylek, E.M., Phillips, K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 285 (2001), 2370–2375.
3. 3 Verma, A., Cairns, J.A., Mitchell, L.B., et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol 30 (2014), 1114–1130.
4. 4 Camm, A.J., Lip, G.Y.H., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:21 (2012), 2719–2747.
5. 5 Spyropoulos, A.C., Douketis, J.D., How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 120 (2012), 2954–2962.
6. 6 Tafur, A.J., McBane, R., Wysokinski, W.E., et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 10 (2012), 261–267.
7. 7 Witt, D.M., Delate, T., Garcia, D.A., et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 172 (2012), 1484–1491.
8. 8 Jaffer, A.K., Brotman, D.J., Bash, L.D., et al. Variations in perioperative warfarin management: outcomes and practice patterns at nine hospitals. Am J Med 123 (2010), 141–150.
9. 9 Douketis, J.D., Spyropoulos, A.C., Spencer, F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e326S–e350.
10. 10 Tafur, A., Douketis, J.D., Perioperative anticoagulant management in patients with atrial fibrillation: practical implications of recent clinical trials. Pol Arch Med Wewn 125:9 (2015), 666–671 Available at: http://www.pamw.pl/en/issue/article/26307106 Accessed October 11, 2015.
11. 11 Schulman, S., Carrier, M., Lee, A.Y., et al. Perioperative management of dabigatran: a prospective cohort study. Circulation 132:3 (2015), 167–173.
12. 12 Narouze, S., Benzon, H.T., Provenzano, D.A., et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med 40:3 (2015), 182–212 Available at: http://journals.lww.com/rapm/Fulltext/2015/05000/Interventional_Spine_and_Pain_Procedures_in.2.aspx Accessed September 28, 2015.
13. 13 Garcia, D., Alexander, J.H., Wallentin, L., et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 124 (2014), 3692–3698.
14. 14 Healey, J.S., Eikelboom, J., Douketis, J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 126 (2012), 343–348.
15. 15 Sherwood, M.W., Douketis, J.D., Patel, M.R., et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 129 (2014), 1850–1859.
16. 16 Beyer-Westendorf, J., Förster, K., Pannach, S., et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124 (2014), 955–962.
17. 17 Kearon, C., A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. J Thromb Haemost 10 (2012), 507–511.
18. 18 Decousus, H., Leizorovicz, A., Parent, F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338 (1998), 409–415.
19. 19 Kearon, C., Akl, E.A., Comerota, A.J., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e419S–e494S.
20. 20 Baron, T.H., Kamath, P.S., McBane, R.D., Antithrombotic therapy and invasive procedures. N Engl J Med 369 (2013), 1077–1080.
21. 21 Vanassche, T., Lauw, M.N., Connolly, S.J., et al. Heparin bridging in peri-procedural management of new oral anticoagulant: a bridge too far?. Eur Heart J 35 (2014), 1831–1833.
22. 22 Siegal, D., Yudin, J., Kaatz, S., et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 126 (2012), 1630–1639.
23. 23 Douketis, J.D., Healey, J.S., Brueckmann, M., et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 113 (2015), 625–632.
24. 24 Douketis, J.D., Spyropoulos, A.C., Kaatz, S., et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 373 (2015), 823–833.
25. 25 Spyropoulos, A.C., Turpie, A.G.G., Perioperative bridging interruption with heparin for the patient receiving long-term anticoagulation. Curr Opin Pulm Med 11 (2005), 373–379.
26. 26 Holbrook, A., Schulman, S., Witt, D.M., et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2012), e152S–e184S.
27. 27 Curtis, R., Schweitzer, A., van Vlymen, J., Reversal of warfarin anticoagulation for urgent surgical procedures. Can J Anaesth 62 (2015), 634–649.
28. 28 Cuker, A., Siegal, D.M., Crowther, M.A., et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64 (2014), 1128–1139.
29. 29 Siegal, D.M., Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39 (2015), 395–402.
30. 30 Glund, S., Moschetti, V., Norris, S., et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 113 (2015), 943–951.
31. 31 Pollack, C.V., Reilly, P.A., Eikelboom, J., et al. Idarucizumab for dabigatran reversal. N Engl J Med 373 (2015), 511–520.
32. 32 Lu, G., DeGuzman, F.R., Hollenbach, S.J., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19 (2013), 446–451.
33. 33 Curnutte, J., Lu, G., Barron, L., et al. ANNEXA-R: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by adexanet alfa (PRT064445), a universal antidote for factor Xa (FXA) inhibitors. J Am Coll Cardiol, 65(10_S), 2015.